Browse by Medical Category
Research at Mass General
Chin-Lee Wu, PhD, MD
Associate Professor of Pathology, Harvard Medical SchoolAssociate Pathologist, Massachusetts General HospitalDirector, Urology Research Laboratory
Massachusetts General Hospital55 Fruit StreetWarren Building, Room 333ABoston, MA 02114Phone: 617-726-8454Fax: 617-724-7803Email: firstname.lastname@example.org
Our laboratory studies the molecular biomarkers of urologic tumors, including cancers of the prostate, bladder and kidney. The long-term goal of these studies is to develop new diagnostic methods and therapeutic regimens for these cancers.
Prostate cancer is the most common cancer and the second leading cause of cancer death of men in the US. We are interested in identifying gene expression profiles associated with the development, diagnosis and prognosis of prostate cancer. We have used laser capture microdissection and DNA microarray techniques to identify a group of genes whose expression can be used to predict the prostate cancer outcome. We are in the process of developing a new gene-based diagnostic test to guide clinical management of prostate cancer. The genes identified by this approach may also be used as new therapeutic targets.
Currently, there is a clinical need to improve the method for imaging prostate cancer in vivo. Through collaboration with Dr. Leo Cheng, MGH Pathology and Radiology, we have identified a metabolomic signature of prostate cancer. We are applying this signature in the development of an in vivo imaging technique for prostate cancer. The new imaging method may help to detect, localize and quantify prostate cancer in vivo. Most prostate cancer death is due to the development of androgen independence. Androgen receptor is responsible for cell growth in both androgen dependent and independent prostate cancers. We identified two novel androgen receptor co-activators that may be involved in the development of androgen independence in prostate cancer. Characterizing these androgen receptor co-activators may lead to new drug targets for androgen independent prostate cancer.
Our laboratory is jointly supported by the MGH Urology and Pathology Departments and the MGH Cancer Center. In addition to our own investigations, we have established productive collaborations with investigators both locally and around the world. We provide clinical, research and technical expertise as well as pathology specimens to these collaborative studies.
Sharron X. Lin, PhD
Bo Wu, MD
Shulin Wu, MD, PhD
Xiuli Xiao, MD
Jianheng Ye, MD
Yanqiong Zhang, PhD
Bibliography of Chin-Lee Wu via PubMed
Gershman B, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu C-L. Smaller prostate gland size and older age predict Gleason score upgrading. Urol Oncol. 2013; 31(7):1033-7.
Dong F, Wang C, Farris AB, Wu S, Lee H, Olumi AF, McDougal WS, Young RH, Wu C-L. Impact on the clinical outcome of prostate cancer by the 2005 International Society of Urological Pathology Modified Gleason Grading System. Am J Surg Pathol. 2012; 36 (6):838-43.
Lu J, Wirth GJ, Wu S, Chen J, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu C-L. A close surgical margin after radical prostatectomy is an independent predictor of recurrence. J Urololgy. 2012; 188(1):91-7.
Zhong W-D, Liang Y-X, Lin SX, Li L, He H-C, Bi X-C, Han Z, Dai Q-S, Ye Y-K, Chen Q-B, Wang Y, Zeng G-H, Zhu G, Zhang Z, Chen Z-N, Wu C-L. Expression of CD147 is associated with prostate cancer progression. Intl J of Cancer. 2012; 130:300–308.
Qin W, Bajaj V, Malinowska I, Lu X, Macconaill L, Wu CL*, Kwiatkowski DJ*. Angiomyolipoma have common mutations in TSC2 but no other common genetic events. PLoS One. 2011; 6(9):e24919. (* equal author contribution).
Wu C-L, Jordan KW, Ratai EM, Sheng J, Adkins CB, DeFeo EM, Jenkins BG, Ying L, McDougal WS, Cheng LL. Metabolomic imaging for human prostate cancer detection. Sci Transl Med 2010; 2, 16ra8.
Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal WS, Wu C-L. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncology 2006; (7):556-64.
Massachusetts General Hospital
Back to Top